IMRX Immuneering Corporation

NASDAQ
$4.27

Immuneering Corporation (IMRX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.3% since its last earnings release on August 5, 2026.

Immuneering Missed Consensus Estimates
Wednesday, August 5, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 7:30 AM ET
Earnings Whisper
-
vs ($0.29)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.76

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immuneering Corporation

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.